Newman Dignan & Sheerar Inc’s Jazz Pharmaceuticals JAZZ Stock Holding History

Newman Dignan & Sheerar Inc’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,300	Closed	-$231K	–	200
2021 Q2	$231K	Hold	1,300	–	–	0.08%	169
2021 Q1	$214K	Buy	1,300 +50	+4%	+$8.23K	0.08%	169
2020 Q4	$206K	Buy	+1,250	New	+$186K	0.03%	166
2019 Q3	–	Sell	-1,765	Closed	-$252K	–	153
2019 Q2	$252K	Buy	+1,765	New	+$237K	0.11%	153

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Newman Dignan & Sheerar Inc's JAZZ Position: Q3 2021 in Review

Newman Dignan & Sheerar Inc sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2021, closing a stake of 1,300 shares — an estimated $231K sold.

Newman Dignan & Sheerar Inc first reported a position in JAZZ in Q2 2019 and held it in 4 quarters. The position peaked at $252K in Q2 2019. 455 funds tracked by Wall St. Rank hold JAZZ as of Q3 2021.

Newman Dignan & Sheerar Inc reported no remaining Jazz Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Newman Dignan & Sheerar Inc sold 1,300 Jazz Pharmaceuticals shares in Q3 2021, an estimated $231K.
Newman Dignan & Sheerar Inc first reported a position in Jazz Pharmaceuticals in Q2 2019 and held it in 4 quarters.
Newman Dignan & Sheerar Inc's Jazz Pharmaceuticals position peaked at $252K in Q2 2019.
455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2021.

Based on Newman Dignan & Sheerar Inc's 13F filing for Q3 2021, filed 7 Oct 2021.